CITIC Securities: Se espera que el antagonista de GDF-15 sea aprobado para el tratamiento de la caquexia tumoral

MetaMuskRat · 2026-03-24T08:09:59+00:00

People's Finance News, March 24 — China Securities research report states that GDF-15 blockers are expected to treat tumor cachexia and enhance PD-(L)1 efficacy. Tumor cachexia affects over 1 million patients globally and currently has no targeted approved drugs; approximately 50-85% of patients develop resistance to PD-(L)1. GDF-15 blockers have demonstrated efficacy in treating cachexia in Phase II clinical proof-of-concept studies and have currently entered the registration clinical stage. China Securities believes GDF-15 blockers are expected to be approved for treating tumor cachexia; the combination of GDF-15 blockers with PD-(L)1 therapy has demonstrated positive data in early clinical stages and multiple Phase II clinical trials are currently underway, though further clinical proof-of-concept validation is still needed.

MetaMuskRat

2026-03-24 08:09:59

人民财讯3月24日电，中信证券研报称，GDF-15阻断剂有望治疗肿瘤恶病质、提升PD-(L)1疗效。肿瘤恶病质全球患者超100万人并且尚无针对性药物获批；约50-85%患者会对PD-(L)1产生耐药。GDF-15阻断剂已在II期临床概念性验证其在恶病质治疗中的疗效，并且目前已进入注册临床阶段，中信证券认为GDF-15阻断剂有望获批治疗肿瘤恶病质；GDF-15阻断剂联合PD-(L)1疗法在早期临床阶段展现出积极数据，目前已经开展多个II期临床试验，但仍需后续临床概念性验证。

Ver originales

Esta página puede contener contenido de terceros, que se proporciona únicamente con fines informativos (sin garantías ni declaraciones) y no debe considerarse como un respaldo por parte de Gate a las opiniones expresadas ni como asesoramiento financiero o profesional. Consulte el Descargo de responsabilidad para obtener más detalles.

1 me gusta